Randomised trial: role of adjuvant AS and zoledronic acid + RT in IR/HR PCa.
1071 p (2003-7). Median follow up 7.4 y. 243 deaths, 91 PC.
Bone metastases in 176p: 47% died PC, 9% died of other causes and 44% remained alive at last follow-up.
All participants BM received secondary therapeutic intervention (STI) using either continuous or intermittent androgen suppression.
“in press”
Accepted 24 July
2016
